» Articles » PMID: 16778892

CRD-BP Mediates Stabilization of BetaTrCP1 and C-myc MRNA in Response to Beta-catenin Signalling

Overview
Journal Nature
Specialty Science
Date 2006 Jun 17
PMID 16778892
Citations 137
Authors
Affiliations
Soon will be listed here.
Abstract

Although constitutive activation of beta-catenin/Tcf signalling is implicated in the development of human cancers, the mechanisms by which the beta-catenin/Tcf pathway promotes tumorigenesis are incompletely understood. Messenger RNA turnover has a major function in regulating gene expression and is responsive to developmental and environmental signals. mRNA decay rates are dictated by cis-acting elements within the mRNA and by trans-acting factors, such as RNA-binding proteins (reviewed in refs 2, 3). Here we show that beta-catenin stabilizes the mRNA encoding the F-box protein betaTrCP1, and identify the RNA-binding protein CRD-BP (coding region determinant-binding protein) as a previously unknown target of beta-catenin/Tcf transcription factor. CRD-BP binds to the coding region of betaTrCP1 mRNA. Overexpression of CRD-BP stabilizes betaTrCP1 mRNA and elevates betaTrCP1 levels (both in cells and in vivo), resulting in the activation of the Skp1-Cullin1-F-box protein (SCF)(betaTrCP) E3 ubiquitin ligase and in accelerated turnover of its substrates including IkappaB and beta-catenin. CRD-BP is essential for the induction of both betaTrCP1 and c-Myc by beta-catenin signalling in colorectal cancer cells. High levels of CRD-BP that are found in primary human colorectal tumours exhibiting active beta-catenin/Tcf signalling implicates CRD-BP induction in the upregulation of betaTrCP1, in the activation of dimeric transcription factor NF-kappaB and in the suppression of apoptosis in these cancers.

Citing Articles

The IGF2BP1 oncogene is a druggable mA-dependent enhancer of YAP1-driven gene expression in ovarian cancer.

Schott A, Simon T, Muller S, Rausch A, Busch B, Glass M NAR Cancer. 2025; 7(1):zcaf006.

PMID: 40008228 PMC: 11850222. DOI: 10.1093/narcan/zcaf006.


IGF2BP1 promotes multiple myeloma with chromosome 1q gain via increasing CDC5L expression in an mA-dependent manner.

Xu J, Wang Y, Ren L, Li P, Liu P Genes Dis. 2024; 12(1):101214.

PMID: 39534570 PMC: 11554607. DOI: 10.1016/j.gendis.2024.101214.


Epigenetic Activation of the CMTM6-IGF2BP1-EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.

Zhu Y, Huang Y, Shi Y, Huang C, Zhao G, Liu Z Adv Sci (Weinh). 2024; 11(47):e2406714.

PMID: 39488785 PMC: 11653652. DOI: 10.1002/advs.202406714.


RNA Binding Proteins as Potential Therapeutic Targets in Colorectal Cancer.

Singh V, Singh A, Liu A, Fuchs S, Sharma A, Spiegelman V Cancers (Basel). 2024; 16(20).

PMID: 39456596 PMC: 11506615. DOI: 10.3390/cancers16203502.


IGF2BP1 phosphorylation in the disordered linkers regulates ribonucleoprotein condensate formation and RNA metabolism.

Hornegger H, Anisimova A, Muratovic A, Bourgeois B, Spinetti E, Niedermoser I Nat Commun. 2024; 15(1):9054.

PMID: 39426983 PMC: 11490574. DOI: 10.1038/s41467-024-53400-4.